ConductScience.org, home

Paper36052238

Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy.

Yang Z and 11 others. Front Oncol, 2022. Cited by 20 papers, by iCite.

Cite this record

ConductScience Library. Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy. Papers, record 36052238. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36052238

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy.
PubMed
Journal
Front Oncol
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
1.67
iCite
Revised in PubMed
2022-09-07
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yang ZZiyi
2Wu ZZiyou
3Xiong YYichen
4Liu SShilei
5Cai CChen
6Shao ZZiyu
7Zhu YYidi
8Song XXiaoling
9Shen WWei
10Wang XXuefeng
11Wu XXiangsong
12Gong WWei

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129993120Extent of lymph node dissection in patients with gallbladder cancer.Br J Surg2018https://conductscience.org/library/papers/29993120PubMed
233593763Protocol for a gallbladder cancer registry study in China: the Chinese Research Group of Gallbladder Cancer (CRGGC) study.BMJ Open2021https://conductscience.org/library/papers/33593763PubMed
333055359Puzzle and Challenge in Routine Extrahepatic Bile Duct Resection for Advanced Gallbladder Carcinoma.Gut Liver2020https://conductscience.org/library/papers/33055359PubMed
434900698Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study.Front Oncol2021https://conductscience.org/library/papers/34900698PubMed
535346072Examination of the characteristics of long-term survivors among patients with gallbladder cancer with liver metastasis who underwent surgical treatment: a retrospective multicenter study (ACRoS1406).BMC Gastroenterol2022https://conductscience.org/library/papers/35346072PubMed
630178032Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.JAMA Oncol2018https://conductscience.org/library/papers/30178032PubMed
729292472Gallbladder Cancer: Complete Resection after Second Line Treatment in Stage IV Disease.J Gastrointest Cancer2019https://conductscience.org/library/papers/29292472PubMed
834676166Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review.Front Oncol2021https://conductscience.org/library/papers/34676166PubMed
926643880Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification.Gastric Cancer2016https://conductscience.org/library/papers/26643880PubMed
1034532118Preoperative serum fibrinogen as a valuable predictor in the nomogram predicting overall survival of postoperative patients with gallbladder cancer.J Gastrointest Oncol2021https://conductscience.org/library/papers/34532118PubMed
1119406039NCCN clinical practice guidelines in oncology: hepatobiliary cancers.J Natl Compr Canc Netw2009https://conductscience.org/library/papers/19406039PubMed
1232945922Locally advanced gallbladder cancer: a review of the criteria and role of imaging.Abdom Radiol (NY)2021https://conductscience.org/library/papers/32945922PubMed
1319652971Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.Cancer Chemother Pharmacol2010https://conductscience.org/library/papers/19652971PubMed
1432878417[Analysis of treatment modalities and prognosis of patients with gallbladder cancer in China from 2010 to 2017].Zhonghua Wai Ke Za Zhi2020https://conductscience.org/library/papers/32878417PubMed
1531950882Trends of gallbladder cancer incidence, mortality, and diagnostic approach in urban Shanghai between 1973 and 2009.Tumori2020https://conductscience.org/library/papers/31950882PubMed
1630611225Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin.BMC Cancer2019https://conductscience.org/library/papers/30611225PubMed
1729227344Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.Ann Surg2019https://conductscience.org/library/papers/29227344PubMed
1833505902Development and Validation of a Nomogram for Predicting Survival in Gallbladder Cancer Patients With Recurrence After Surgery.Front Oncol2020https://conductscience.org/library/papers/33505902PubMed
1931825009Long term recurrence free survival in a stage IV gallbladder cancer treated with chemotherapy plus trastuzumab and salvage liver resection.Ann Hepatobiliary Pancreat Surg2019https://conductscience.org/library/papers/31825009PubMed
2033028805Overview of current targeted therapy in gallbladder cancer.Signal Transduct Target Ther2020https://conductscience.org/library/papers/33028805PubMed

See all 31 referencesDownload CSV of references

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
42649595Efficacy and Safety of First-Line Chemotherapy With Gemcitabine Plus Nab-Paclitaxel in Unresectable Gallbladder Cancer.Cancer Med2026https://conductscience.org/library/papers/42649595PubMed
42477458Splicing-mediated control of hnRNPD isoform switching by SRSF2 drives PD-L1-dependent immune evasion in gallbladder cancer.Oncogene2026https://conductscience.org/library/papers/42477458PubMed
42324334Association of surgical extent with survival in locally advanced gallbladder cancer based on propensity score matching.Sci Rep2026https://conductscience.org/library/papers/42324334PubMed
41820390Alkaloids from Evodia rutaecarpa inhibit the occurrence and development of gallbladder cancer in vivo and in vitro.Sci Rep2026https://conductscience.org/library/papers/41820390PubMed
40696595Predictive and prognostic models and visualizations of distant metastasis in gallbladder cancer.Medicine (Baltimore)2025https://conductscience.org/library/papers/40696595PubMed
40670935An end-to-end interpretable machine-learning-based framework for early-stage diagnosis of gallbladder cancer using multi-modality medical data.BMC Cancer2025https://conductscience.org/library/papers/40670935PubMed
40485726Neoadjuvant radiotherapy combined with targeted and immune therapies achieves a pathological complete response in borderline resectable gallbladder cancer: a case report and literature review.Front Oncol2025https://conductscience.org/library/papers/40485726PubMed
39655073Efficacy of neoadjuvant therapy and lymph node dissection in advanced gallbladder cancer without distant metastases: a SEER database analysis.Front Oncol2024https://conductscience.org/library/papers/39655073PubMed
39606221Comparison of treatment models for single primary advanced gallbladder cancer.Front Immunol2024https://conductscience.org/library/papers/39606221PubMed
39436624A case of successful conversion surgery for unresectable gallbladder cancer treated with durvalumab in combination with gemcitabine plus cisplatin.Clin J Gastroenterol2025https://conductscience.org/library/papers/39436624PubMed
39105433Prognostic Impact of Neoadjuvant Chemotherapy in Localized or Locoregionally Advanced Gallbladder Cancer: A Population-Based and Propensity Score Matched SEER Analysis.Cancer Control2024https://conductscience.org/library/papers/39105433PubMed
39064241Risk Factors and Prognostic Factors in GBC.J Clin Med2024https://conductscience.org/library/papers/39064241PubMed
38398143ANLN Promotes the Proliferation and Migration of Gallbladder Cancer Cells via STRA6-Mediated Activation of PI3K/AKT Signaling.Cancers (Basel)2024https://conductscience.org/library/papers/38398143PubMed
38123314PD-L1 inhibitor plus gemcitabine and cisplatin therapy followed by conversion surgery for initially unresectable advanced gallbladder cancer.BMJ Case Rep2023https://conductscience.org/library/papers/38123314PubMed
37927929Impact of conversion surgery after chemotherapy in patients with initially unresectable and recurrent biliary tract cancer.Ann Gastroenterol Surg2023https://conductscience.org/library/papers/37927929PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CEACAM31084PubTator's text mininghttps://conductscience.org/library/genes/1084NCBI Gene
MUC1694025PubTator's text mininghttps://conductscience.org/library/genes/94025NCBI Gene
TENM110178PubTator's text mininghttps://conductscience.org/library/genes/10178NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36052238

GET https://conductscience.org/api/papers/v1/36052238/references?page=2